Miguel-Angel Berciano-Guerrero (Miguel A Berciano-Guerrero, Miguel Ángel Berciano-Guerrero, Miguel-Ángel Berciano-Guerrero)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Ejection Fraction

Chemotherapy Induced

Top Venues

International journal of molecular sciences

Translational lung cancer research

Life (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Mora Guardamagna, May-Lucie Meyer, Miguel-Angel Berciano-Guerrero, Andres Mesas-Ruiz, Manuel Cobo-Dols, Elisabeth Perez-Ruiz, Alexandra Cantero Gonzalez, Rocío Lavado-Valenzuela, Isabel Barragán, Javier Oliver, Alicia Garrido-Aranda, Martina Alvarez, Antonio Rueda-Dominguez, María Isabel Queipo-Ortuño, Emilio Alba Conejo, Jose Carlos Benitez
Oncogene-addicted solid tumors and microbiome-lung cancer as a main character: a narrative review. Translational lung cancer research 13 (8) (2024)
Sarah A Weiss, Mario Sznol, Montaser Shaheen, Miguel-Angel Berciano-Guerrero, Eva Muñoz Couselo, Delvys Rodriguez Abreu, Valentina Boni, Lynn M Schuchter, Maria Gonzales Cao, Ana M Arance, Wei Wei, Apar Kishor Ganti, Ralph J Hauke, Alfonso Berrocal, Nicholas O Iannotti, Frank J Hsu, Harriet M Kluger
A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Philip Clingan, Rahul Ladwa, Daniel Brungs, Dean Laurence Harris, Margaret McGrath, Susan Arnold, Jermaine Coward, Samuel Fourie, Andriy Kurochkin, Daniel R Malan, Andrew Mant, Vinay Sharma, Hong Shue, Andrea Tazbirkova, Miguel-Angel Berciano-Guerrero, Chaiyut Charoentum, Stéphane Dalle, Arunee Dechaphunkul, Oleksandr Dudnichenko, Piotr Koralewski, Iwona Lugowska, Henri Montaudié, Eva Muñoz-Couselo, Virote Sriuranpong, James Oliviero, Jayesh Desai
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. Journal for immunotherapy of cancer 11 (10) (2023)
Miguel-Angel Berciano-Guerrero
Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer. Cancer medicine (2022)
Miguel-Angel Berciano-Guerrero, Mora Guardamagna, Elisabeth Perez-Ruiz, Jose-Miguel Jurado, Isabel Barragán, Antonio Rueda-Dominguez
Treatment of Metastatic Melanoma at First Diagnosis: Review of the Literature. Life (Basel, Switzerland) 12 (9) (2022)
Javier Oliver, Juan-Luis Onieva-Zafra, Maria Garrido-Barros, Miguel-Angel Berciano-Guerrero, Alfonso Sánchez-Muñoz, María José Lozano, Angela Farngren, Martina Alvarez, Beatriz Martínez-Gálvez, Elisabeth Perez-Ruiz, Emilio Alba, Manuel Cobo, Antonio Rueda-Domínguez, Isabel Barragán
Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma. Biomedicines 10 (10) (2022)
Juan-Luis Onieva-Zafra, Qingyang Xiao, Miguel-Angel Berciano-Guerrero, Aurora Laborda-Illanes, Carlos de Andrea, Patricia Chaves Guerrero, Pilar Piñeiro, Alicia Garrido-Aranda, Elena Gallego, Belén Sojo, Laura Gálvez Carvajal, Rosario Chica-Parrado, Juan Daniel Prieto Cuadra, Elisabeth Perez-Ruiz, Angela Farngren, María José Lozano, Martina Alvarez, Pedro Jiménez, Alfonso Sánchez-Muñoz, Javier Oliver, Manuel Cobo, Emilio Alba, Isabel Barragán
High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade. International journal of molecular sciences 23 (16) (2022)
Miguel-Angel Berciano-Guerrero, Rocío Lavado-Valenzuela, Aurelio A Moya-García, Luis de la Cruz Merino, Fátima Toscano, Javier Valdivia, Victoria Castellón, Fernando Henao-Carrasco, Pilar Sancho, Juan-Luis Onieva-Zafra, Ismael Navas-Delgado, Antonio Rueda-Dominguez, Elisabeth Perez-Ruiz, Emilio Alba
Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy. Biomedicines 10 (2) (2022)
Mora Guardamagna, Miguel-Angel Berciano-Guerrero, Beatriz Villaescusa-González, Elisabeth Perez-Ruiz, Javier Oliver, Rocío Lavado-Valenzuela, Antonio Rueda Domínguez, Isabel Barragán, María Isabel Queipo-Ortuño
Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition. International journal of molecular sciences 23 (19) (2022)
Maria Gonzales Cao, Clara Mayo de Las Casas, Juana Oramas, Miguel-Angel Berciano-Guerrero, Luis de la Cruz, Pablo Cerezuela, Ana Arance, Eva Muñoz-Couselo, Enrique Espinosa, Teresa Puertolas, Roberto Diaz Beveridge, Sebastian Ochenduszko, Maria-Jose Villanueva, Laura Basterretxea, Lorena Bellido, Delvys Rodriguez, Begoña Campos Balea, Clara Montagut, Ana Drozdowskyj, Miguel Ángel Molina-Vila, Jose Antonio Lopez-Martin, Alfonso Berrocal
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nature communications 12 (1) (2021)